PhoenixBio Announces Partnership with Inotiv

PhoenixBio Co., Ltd. (“PhoenixBio”) announced today that it has entered into an agreement to partner with Inotiv, Inc. (“Inotiv”) in providing pre-clinical research services utilizing the PXB-mouse^® (cDNA-uPA/SCID mouse model with a humanized liver).

Inotiv will provide clients with an option of research services using the PXB-mouse^® through Inotiv’s contract study site in North America and will expand PhoenixBio’s capacity in satisfying the growing demand in services with its proprietary animal model.

The PXB-mouse^® has been the most utilized humanized liver chimeric mouse model with up to 95% engraftment of human hepatocytes. With growing interest in humanized liver models across a range of various applications, the addition of Inotiv’s capacity in providing services in drug metabolism and pharmacokinetics (DMPK), toxicity, oligonucleotide therapeutics, gene therapy, and other applications will expand access to PhoenixBio’s lead products.

“Combining the efforts of our two companies to provide access to study services with the most advanced and most utilized humanized liver chimeric mouse model opens new horizons in helping clients in the pharmaceutical and biotechnology industries to develop effective and safe new therapies with the overall goal of improving global human health and quality of life,” said Mr. Takashi Shimada, President & CEO of PhoenixBio. “We look forward to strengthening our capability in satisfying a global demand for PhoenixBio’s technology.”

“Inotiv has been very active in the development and application of new research models for many years. The collaboration with PhoenixBio brings unique capabilities allowing us to provide broader service to Inotiv’s clients and enhance the predictive power of our non-clinical offerings,” said Dr. John Sagartz, Chief Strategy Officer and Director of Inotiv.

About PhoenixBio Co, Ltd.: A Japanese public company and a commercial scale supplier of the PXB-mouse^® (a humanized liver chimeric mouse model) and PXB-cells^® (human hepatocyte freshly isolated from the PXB-mice). The model features a high replacement of human hepatocytes in the liver, ensuring accurate and predictable translatability in pre-clinical in vivo studies resulting in accelerated discovery pipelines. The PXB-mouse^® provides clinically relevant and translatable data in the fields of hepatitis virology (HBV, HCV, HBV/HDV), DMPK and safety, gene-based therapeutics, and non-viral liver diseases (NASH/NAFLD).

About Inotiv, Inc.: Inotiv is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies and medical research organizations. The Company focuses on developing innovative services supporting its clients’ discovery and development objectives for improved decision-making and accelerated goal attainment. The Company’s products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market.